Alkermes, Inc.
The purpose of this study is to continue to measure the safety, tolerability, and durability of treatment effect in subjects with Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), or Idiopathic Hypersomnia (IH) when taking ALKS 2680 tablets.
Inclusion Criteria: * Was eligible for and has completed end of treatment visit of ALKS 2680 eligible parent study in NT1, NT2 or IH. The current eligible studies are ALKS 2680-201 (Vibrance-1), ALKS 2680-202 (Vibrance-2) and ALKS 2680-203 (Vibrance-3), ALKS 2680-302 (Brilliance NT1) , ALKS 2680-303 (Brilliance NT2) , ALKS 2680-304 (Brilliance NT 1) * Is willing and able, and in the opinion of the treating physician can safely discontinue any medications prescribed for the management of narcolepsy symptoms, as applicable, for 5 half-lives prior to Day 1 (for re-entry subjects), and for the du…
Oral tablet containing 4 mg of ALKS 2680 for once daily administration
Oral tablet containing 6 mg of ALKS 2680 for once daily administration
Oral tablet containing 8 mg of ALKS 2680 for once daily administration
Oral tablet containing 10 mg of ALKS 2680 for once daily administration
Oral tablet containing 14 mg of ALKS 2680 for once daily administration
Oral tablet containing 18 mg of ALKS 2680 for once daily administration